Novel tumor antigens for melanoma and uses thereof

A method of treating cancer in a subject comprising administering to the subject an effective amount of:

• (a) a TAP comprising or consisting of any one of the sequences set forth in SEQ ID NOs:
• 1-505 or any combination thereof, or a synthetic long peptide (SLP) comprising at least one of the sequences set forth in SEQ ID NOs:
• 1-505;
• (b) at least one nucleic acid encoding the TAP, combination thereof or SLP defined in (a);
• (c) a vesicle or particle comprising the TAP, combination thereof or SLP defined in (a) or the at least one nucleic acid defined in (b);
• (d) a composition comprising the TAP, combination thereof or SLP defined in (a), the at least one nucleic acid defined in (b), or the vesicle or particle defined in (c), and a pharmaceutically acceptable carrier;
• (e) a vaccine comprising the TAP, combination thereof or SLP defined in (a), the at least one nucleic acid defined in (b), the vesicle or particle defined in (c), or the composition defined in (d), and an adjuvant;
• (f) a cell expressing at its surface major histocompatibility complex (MHC) class I molecules comprising the TAP or combination thereof defined in (a) in their peptide binding groove;
• (g) a cell expressing at its cell surface a T-cell receptor (TCR) or a chimeric antigen receptor (CAR) that specifically recognizes MHC class I molecules expressed at the surface of the cell defined in (f);
• or
• (h) a soluble TCR, an antibody or an antigen-binding fragment thereof, or a CAR, that specifically binds to the MHC class I molecules expressed at the surface of the cell defined in (f), or a nucleic acid encoding said soluble TCR, antibody, antigen-binding fragment thereof, or CAR.